Olema Pharmaceuticals
Market cap $633M 87.6M shares (10-Q, Nov 5, 2026) × $7.22 close Nov 17, 2026
Most recent annual filing: 2026-03-16
- OP-3136 trial start4Q 2026OP-3136 trial start, 4Q 2026, routine
- Olema corporate updateNov 2026Olema corporate update, Nov 2026, routine
- Olema industry event readoutDec 8–11, 2026Olema industry event readout, Dec 8–11, 2026, notable
- Giredestrant PDUFA dateDec 18, 2026Giredestrant PDUFA date, Dec 18, 2026, major
- Palazestrant topline1Q 2027Palazestrant topline, 1Q 2027, thesis-defining
- OPERA-01 topline1Q 2027OPERA-01 topline, 1Q 2027, major
- Palazestrant NDA filing2027Palazestrant NDA filing, 2027, material
- Credit facility financingJan 31, 2027Credit facility financing, Jan 31, 2027, notable
- OP-3136 interim1H/mid-2027OP-3136 interim, 1H/mid-2027, notable
- Olema CEO leadership updateJun 8, 2027Olema CEO leadership update, Jun 8, 2027, routine
- Palazestrant + ribociclib topline2028Palazestrant + ribociclib topline, 2028, major
- Palazestrant FDA approval2028Palazestrant FDA approval, 2028, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (3 active programs)
OP-3136
Capital (as filed)
- Cash
- $47.5M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $366M Sep 30, 2026
- Operating cash flow
- −$47.1M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $414M cash, runway through mid-2028 per the update of Nov 10, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (2)
- 2026-11-11 UPDATE: Olema Pharmaceuticals (OLMA) - Two Tripwires Clear, One Trips 🔒 Paid
- 2026-10-28 Olema Pharmaceuticals (OLMA) - Scientific Deep Dive for Palazestrant, OP-3136 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (2 calls)
Every verdict Biotech Distilled has published on Olema Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-10-28 Watch Olema Pharmaceuticals (OLMA) - Scientific Deep Dive for Palazestrant, OP-3136 and Pipeline Products Olema is cash plus one binary on an ESR1 wild-type endpoint no oral degrader has delivered, with the price implying only ~7% odds of that outcome; revisit only if OPERA-01 shows a significant wild-type benefit.
- 2026-11-11 Avoid UPDATE: Olema Pharmaceuticals (OLMA) - Two Tripwires Clear, One Trips OPERA-02 continuing at full cost after SERENA-4 with no design or disclosure change triggered a pre-stated PASS rule, and accrued liabilities understate the burn, lowering read-out cash estimates.
- Avoid call · opened Nov 11, 2026 at $8.04 · -10.2% vs XBI -7.1% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (2 quotes from 2 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“The Original Credit Facility was scheduled to mature on August 1, 2027 (the "Original Maturity Date").”
matched to Credit facility · financing
-
-
-
“The Original Credit Facility was scheduled to mature on August 1, 2027 (the "Original Maturity Date").”
matched to Credit facility · financing
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (23)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Nov 2, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 12, 2026ReleaseOlema Oncology Announces Corporate Name Change
- Nov 12, 20268-KCurrent report: charter / bylaws / fiscal year, Reg FD disclosure, other events · EX-99.1
- Nov 10, 2026ReleaseOlema Oncology Reports Third Quarter 2026 Financial and Operating Results→ BD updateSummary on the 8-K
- Nov 10, 20268-KCurrent report: results of operations · EX-99.1→ BD updateOlema's Q3 10-Q reaffirms OPERA-01 reads in Q1 2027 with $413.8M in cash — more runway than I estimated — but the burn rate accelerated sharply and December SABCS data drops are now on the calendar for three combination programs.
- Nov 10, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 4, 2026ReleaseOlema Oncology to Present Combination Data from the Palazestrant and OP-3136 Programs at the 2026 San Antonio Breast Cancer Symposium
- Nov 2, 2026ReleaseOlema Oncology to Participate in Upcoming Investor Conferences
- Oct 16, 2026SCHEDULE 13D/A13D amendment
- Oct 15, 20268-KCurrent report: officer / director change
- Aug 13, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
- Aug 10, 20268-KCurrent report: results of operations · EX-99.1
- Aug 10, 202610-QQuarterly report
- Jun 23, 20268-KCurrent report: shareholder vote
- May 26, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- May 21, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- May 12, 20268-KCurrent report: results of operations · EX-99.1
- May 12, 202610-QQuarterly report
- May 1, 20268-KCurrent report: material agreement, debt / obligation
- Apr 29, 2026DEFA14AProxy soliciting material
- Apr 29, 2026DEF 14AProxy statement
- Apr 29, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
- Mar 16, 20268-KCurrent report: results of operations · EX-99.1
- Mar 16, 202610-KAnnual report
9 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Aug 6, 2026SCHEDULE 13G/A13G amendment
- Jul 29, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- Apr 29, 2026ARSAnnual report to shareholders
- Mar 20, 2026SCHEDULE 13GPassive >5% holder (13G)
- Mar 16, 2026S-8Employee plan registration
- Mar 6, 2026SCHEDULE 13G/A13G amendment